Small-molecule inhibitors of the c-Fes protein-tyrosine kinase

Chemistry and Biology

Volumn 19, Issue 4, 2012, Pages 529-540

  Hellwig, Sabine ^a   Miduturu, Chandra V ^b   Kanda, Shigeru ^c,d   Zhang, Jianming ^b   Filippakopoulos, Panagis ^e   Salah, Eidarus ^e   Deng, Xianming ^b   Choi, Hwan Geun ^b   Zhou, Wenjun ^b   Hur, Wooyoung ^b   Knapp, Stefan ^e   Gray, Nathanael S ^b   Smithgall, Thomas E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NAGASAKI UNIVERSITY   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANAPLASTIC LYMPHOMA KINASE; HG 514501; HG 515001; HG 55601; HG 59101; HG 712701; HG 72701; HG 79201; METHIONINE; PROTEIN KINASE FES; PROTEIN KINASE INHIBITOR; PROTEIN SH2; PROTEIN TYROSINE KINASE INHIBITOR; TAE 684; UNCLASSIFIED DRUG; WH 41242; WH 41991; WH 41992; WZ 4241; WZ 4242; WZ 4243; WZ 4247; WZ 4491; WZ 44910; WZ 4498; WZ 4499; XMD 5130; XMD 63;

ARTICLE; BIOLOGICAL FUNCTIONS; CELL ASSAY; CRYSTAL STRUCTURE; DRUG POTENCY; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS;

ANIMALS; BINDING SITES; CELL DIFFERENTIATION; CELL LINE; CERCOPITHECUS AETHIOPS; COMPUTER SIMULATION; COS CELLS; CRYSTALLOGRAPHY, X-RAY; MICE; MICROTUBULES; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-FES; PYRIMIDINES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SRC HOMOLOGY DOMAINS;

EID: 84860147569     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2012.01.020     Document Type: Article

References (56)

1. A. Bardelli, D.W. Parsons, N. Silliman, J. Ptak, S. Szabo, S. Saha, S. Markowitz, J.K. Willson, G. Parmigiani, and K.W. Kinzler Mutational analysis of the tyrosine kinome in colorectal cancers Science 300 2003 949
2. R.T. Bossi, M.B. Saccardo, E. Ardini, M. Menichincheri, L. Rusconi, P. Magnaghi, P. Orsini, N. Avanzi, A.L. Borgia, and M. Nesi Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors Biochemistry 49 2010 6813 6825
3. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
4. S.D. Briggs, and T.E. Smithgall SH2-kinase linker mutations release Hck tyrosine kinase and transforming activities in Rat-2 fibroblasts J. Biol. Chem. 274 1999 26579 26583
5. A. Car, G. Mattia, E. Montesoro, I. Parolini, G. Russo, M.P. Colombo, and C. Peschle c-fes expression in ontogenetic development and hematopoietic differentiation Oncogene 9 1994 739 747
6. H.Y. Cheng, A.P. Schiavone, and T.E. Smithgall A point mutation in the N-terminal coiled-coil domain releases c-Fes tyrosine kinase activity and survival signaling in myeloid leukemia cells Mol. Cell. Biol. 21 2001 6170 6180
7. A.W. Craig FES/FER kinase signaling in hematopoietic cells and leukemias Front. Biosci. 17 2012 861 875
8. F.J. Delfino, H. Stevenson, and T.E. Smithgall A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer J. Biol. Chem. 281 2006 8829 8835
9. L. Emert-Sedlak, T. Kodama, E.C. Lerner, W. Dai, C. Foster, B.W. Day, J.S. Lazo, and T.E. Smithgall Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds ACS Chem. Biol. 4 2009 939 947
10. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 60 2004 2126 2132
11. J.R. Engen, T.E. Wales, J.M. Hochrein, M.A. Meyn 3rd, S. Banu Ozkan, I. Bahar, and T.E. Smithgall Structure and dynamic regulation of Src-family kinases Cell. Mol. Life Sci. 65 2008 3058 3073
12. P. Evans SCALA - scale together multiple observations of reflections 2007 MRC Laboratory of Molecular Biology Cambridge
13. P. Filippakopoulos, M. Kofler, O. Hantschel, G.D. Gish, F. Grebien, E. Salah, P. Neudecker, L.E. Kay, B.E. Turk, and G. Superti-Furga Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation Cell 134 2008 793 803
14. A.V. Galkin, J.S. Melnick, S. Kim, T.L. Hood, N. Li, L. Li, G. Xia, R. Steensma, G. Chopiuk, and J. Jiang Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK Proc. Natl. Acad. Sci. USA 104 2007 270 275
15. P.A. Greer, K. Meckling-Hansen, and T. Pawson The human c-fps/fes gene product expressed ectopically in rat fibroblasts is nontransforming and has restrained protein-tyrosine kinase activity Mol. Cell. Biol. 8 1988 578 587
16. P. Greer, J. Haigh, G. Mbamalu, W. Khoo, A. Bernstein, and T. Pawson The Fps/Fes protein-tyrosine kinase promotes angiogenesis in transgenic mice Mol. Cell. Biol. 14 1994 6755 6763
17. P.A. Greer, S. Kanda, and T.E. Smithgall The contrasting oncogenic and tumor suppressor roles of FES Front. Biosci. (Schol. Ed.) 4 2011 489 501
18. J. Haigh, J. McVeigh, and P. Greer The fps/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the trans-golgi network Cell Growth Differ. 7 1996 931 944
19. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
20. S. Hellwig, and T.E. Smithgall Structure and regulation of the c-Fes protein-tyrosine kinase Front. Biosci. 17 2012 3146 3155
21. S.J. Hjermstad, K.L. Peters, S.D. Briggs, R.I. Glazer, and T.E. Smithgall Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by its src homology 2 domain and major autophosphorylation site (Tyr-713) Oncogene 8 1993 2283 2292
22. C.C. Huang, C. Hammond, and J.M. Bishop Nucleotide sequence and topography of chicken c-fps. Genesis of a retroviral oncogene encoding a tyrosine-specific protein kinase J. Mol. Biol. 181 1985 175 186
23. T. Itoh, and P. De Camilli BAR, F-BAR (EFC) and ENTH/ANTH domains in the regulation of membrane-cytosol interfaces and membrane curvature Biochim. Biophys. Acta 1761 2006 897 912
24. S. Kanda, and Y. Miyata The c-Fes protein tyrosine kinase as a potential anti-angiogenic target in cancer Front. Biosci. 16 2011 1024 1035
25. S. Kanda, E.C. Lerner, S. Tsuda, T. Shono, H. Kanetake, and T.E. Smithgall The nonreceptor protein-tyrosine kinase c-Fes is involved in fibroblast growth factor-2-induced chemotaxis of murine brain capillary endothelial cells J. Biol. Chem. 275 2000 10105 10111
26. S. Kanda, Y. Miyata, H. Kanetake, and T.E. Smithgall Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review) Int. J. Mol. Med. 20 2007 113 121
27. S. Kanda, Y. Miyata, H. Kanetake, and T.E. Smithgall Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells Int. J. Oncol. 34 2009 89 96
28. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, and P.T. Edeen A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
29. J. Kim, and R.A. Feldman Activated Fes protein tyrosine kinase induces terminal macrophage differentiation of myeloid progenitors (U937 cells) and activation of the transcription factor PU.1 Mol. Cell. Biol. 22 2002 1903 1918
30. J. Kim, Y. Ogata, H. Ali, and R.A. Feldman The Fes tyrosine kinase: a signal transducer that regulates myeloid-specific gene expression through transcriptional activation Blood Cells Mol. Dis. 32 2004 302 308
31. C.E. Laurent, F.J. Delfino, H.Y. Cheng, and T.E. Smithgall The human c-Fes tyrosine kinase binds tubulin and microtubules through separate domains and promotes microtubule assembly Mol. Cell. Biol. 24 2004 9351 9358
32. E.C. Lerner, and T.E. Smithgall SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo Nat. Struct. Biol. 9 2002 365 369
33. A.G.W. Leslie, and H. Powell MOSFLM 2007 MRC Laboratory of Molecular Biology Cambridge
34. J. Li, and T.E. Smithgall Fibroblast transformation by Fps/Fes tyrosine kinases requires Ras, Rac, and Cdc42 and induces extracellular signal-regulated and c-Jun N-terminal kinase activation J. Biol. Chem. 273 1998 13828 13834
35. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2 2006 358 364
36. A.J. McCoy, R.W. Grosse-Kunstleve, L.C. Storoni, and R.J. Read Likelihood-enhanced fast translation functions Acta Crystallogr. D Biol. Crystallogr. 61 2005 458 464
37. V.A. McPherson, S. Everingham, R. Karisch, J.A. Smith, C.M. Udell, J. Zheng, Z. Jia, and A.W. Craig Contributions of F-BAR and SH2 domains of Fes protein tyrosine kinase for coupling to the FcepsilonRI pathway in mast cells Mol. Cell. Biol. 29 2009 389 401
38. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. D Biol. Crystallogr. 53 1997 240 255
39. J. Painter, and E.A. Merritt Optimal description of a protein structure in terms of multiple groups undergoing TLS motion Acta Crystallogr. D Biol. Crystallogr. 62 2006 439 450
40. A. Perrakis, R. Morris, and V.S. Lamzin Automated protein model building combined with iterative structure refinement Nat. Struct. Biol. 6 1999 458 463
41. S.M. Rodems, B.D. Hamman, C. Lin, J. Zhao, S. Shah, D. Heidary, L. Makings, J.H. Stack, and B.A. Pollok A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases Assay Drug Dev. Technol. 1 2002 9 19
42. A.J. Roebroek, J.A. Schalken, J.S. Verbeek, A.M. Van den Ouweland, C. Onnekink, H.P. Bloemers, and W.J. Van de Ven The structure of the human c-fes/fps proto-oncogene EMBO J. 4 1985 2897 2903
43. J.A. Rogers, H.Y. Cheng, and T.E. Smithgall Src homology 2 domain substitution modulates the kinase and transforming activities of the Fes protein-tyrosine kinase Cell Growth Differ. 11 2000 581 592
44. G.D. Roodman Mechanisms of bone metastasis N. Engl. J. Med. 350 2004 1655 1664
45. I. Sadowski, J.C. Stone, and T. Pawson A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps Mol. Cell. Biol. 6 1986 4396 4408
46. W. Sangrar, R.A. Zirgnibl, Y. Gao, W.J. Muller, Z. Jia, and P.A. Greer An identity crisis for fps/fes: oncogene or tumor suppressor? Cancer Res. 65 2005 3518 3522
47. J.M. Shaffer, S. Hellwig, and T.E. Smithgall Bimolecular fluorescence complementation demonstrates that the c-Fes protein-tyrosine kinase forms constitutive oligomers in living cells Biochemistry 48 2009 4780 4788
48. J.M. Shaffer, and T.E. Smithgall Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer Genes Chromosomes Cancer 48 2009 272 284
49. S.P. Snyder, and G.H. Theilen Transmissible feline fibrosarcoma Nature 221 1969 1074 1075
50. Y. Takashima, F.J. Delfino, J.R. Engen, G. Superti-Furga, and T.E. Smithgall Regulation of c-Fes tyrosine kinase activity by coiled-coil and SH2 domains: analysis with Saccharomyces cerevisiae Biochemistry 42 2003 3567 3574
51. E. Voisset, S. Lopez, P. Dubreuil, and P. De Sepulveda The tyrosine kinase FES is an essential effector of KITD816V proliferation signal Blood 110 2007 2593 2599
52. E. Voisset, S. Lopez, A. Chaix, C. Georges, K. Hanssens, T. Prébet, P. Dubreuil, and P. De Sepulveda FES kinases are required for oncogenic FLT3 signaling Leukemia 24 2010 721 728
53. L.H. Wang, R. Feldman, M. Shibuya, H. Hanafusa, M.F. Notter, and P.C. Balduzzi Genetic structure, transforming sequence, and gene product of avian sarcoma virus UR1 J. Virol. 40 1981 258 267
54. Y. Wang, and D.W. Grainger siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption Pharm. Res. 27 2010 1273 1284
55. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
56. W. Zhou, D. Ercan, L. Chen, C.H. Yun, D. Li, M. Capelletti, A.B. Cortot, L. Chirieac, R.E. Iacob, and R. Padera Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462 2009 1070 1074